Key result
Transseptal endocardial LV lead implantation is linked to improved LVEF but carries ~7% thromboembolic risk.
Why the study?
The long-term efficacy and safety of transseptal endocardial left ventricular lead implantation remained to be investigated.
Observational (n=54)
No
p-value: p=<0.05
Transseptal endocardial left ventricular lead implantation is an effective approach for CRT but carries a substantial thromboembolic risk of 7% despite anticoagulation.
No takes yet. Share an insight, caveat, or question.
Should not yet change CRT lead strategies; leaves open net benefit of transseptal endocardial LV pacing pending randomized data.
Gellér et al. (2019) conducted an observational in Heart failure (NYHA III-IV stage) requiring cardiac resynchronization therapy (n=54). Transseptal endocardial left ventricular lead implantation (TELVLI) was evaluated on Long-term efficacy (LVEF improvement) and safety (p=<0.05). Transseptal endocardial left ventricular lead implantation improved median LVEF from 27% to 33% (P<0.05) but was associated with a substantial 7% thromboembolic risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: